RPG Life Sciences Q2 Revenue Rises 16.5% To Rs 211.6 Crore

What happened

RPG Life Sciences reported a 16.5 per cent year-on-year rise in revenue from operations to Rs 211.6 crore for the second quarter of FY27, crossing the Rs 200-crore quarterly revenue milestone, with adjusted EBITDA up 15 per cent to Rs 50.1 crore.

Confirmed

Global impact / market context

Faster revenue growth alongside a 23.7 per cent adjusted EBITDA margin, which means profit left after everyday operating costs, suggests the company is converting sales into operating profit without giving up efficiency. That supports internal cash generation for future capital spending and reduces reliance on borrowed money.

Analyst inference

The domestic formulations business grew 11.6 per cent, beating the broader Indian pharmaceutical market, and the company entered the top 50 rankings and became the fourth-fastest-growing firm in that market, per Pharmarack MAT September 2026 data. This points to share gains rather than only market-wide growth.

Analyst inference

What to watch

1. Adjusted EBITDA figures exclude one-off API acquisition and restructuring costs of Rs 5.5 crore, so reported profit including those costs will be lower than the adjusted numbers shown. Confirmed
2. Watch whether the domestic formulations business keeps growing faster than the Indian pharmaceutical market in coming quarters, since that outperformance is a stated driver of the current growth. Proposed
3. Monitor gross margin, which means profit per sale after direct product costs, after the 260-basis-point expansion, since holding that gain would signal the pricing and product-mix benefits persist. Analyst inference

Evidence

• Original source link unavailable